Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 5.1. Drug Class
- 5.2. Route of Administration
- 5.3. Age Group
- 5.4. End-User
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
- 6.1. Chemotherapy Drugs
- 6.2. Targeted Therapy Drugs
- 6.3. Immunotherapy Drugs
- 6.4. Hormonal Therapy Drugs
- 6.5. Other Drug Classes
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
- 7.1. Oral
- 7.2. Intravenous
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Age Group
- 8.1. Pediatric Patients (0-17 years)
- 8.2. Young Adults (18-39 years)
- 8.3. Middle-Aged Adults (40-64 years)
- 8.4. Older Adults (65+ years)
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-User
- 9.1. Hospitals
- 9.2. Cancer Treatment Centers
- 9.3. Ambulatory Surgical Centers (ASCs)
- 9.4. Specialized Clinics
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. East Asia
- 10.6. South Asia & Pacific
- 10.7. MEA
- 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. MEA Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. Sales Forecast 2024 to 2034 by Drug Class, Route of Administration, Age Group, and End-User for 30 Countries
- 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 20. Company Profile
- 20.1. Janssen Pharmaceuticals (J&J)
- 20.2. AstraZeneca
- 20.3. Bayer AG
- 20.4. Bristol-Myers Squibb Company
- 20.5. Cadila Pharmaceuticals Ltd.
- 20.6. Eli Lilly and Company
- 20.7. F. Hoffmann-La Roche Ltd.
- 20.8. Merck & Co. Inc.
- 20.9. Novartis AG
- 20.10. Ono Pharmaceutical
- 20.11. Pfizer, Inc.
